Brain blood vessel abnormalities in Alagille usually stable over time
Blood vessel abnormalities in the brain, such as unusually narrow or bulging vessels, are common in children with Alagille syndrome and remain generally stable over…
Marisa Wexler, MS, Senior Science Writer — 
Articles by Marisa Wexler
FDA to decide on full approval for Ocaliva in treating adults with PBC
The U.S. Food and Drug Administration (FDA) agreed to review an application seeking full and formal approval of Ocaliva (obeticholic acid) as a…
FDA approves Mirum’s Livmarli for PFIC patients ages 5 and older
The U.S. Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals’ Livmarli (maralixibat) to reduce pruritus, or itching, in adults and children, 5 years…
Probiotics may help women with ICP, but risks not yet known
Women with intrahepatic cholestasis of pregnancy (ICP) show lesser diversity across their gut bacteria than do other pregnant women, a study reports. Its findings…
Survodutide lowers severe fatty liver disease severity in Phase 2 trial
Weekly injections under the skin of the experimental therapy survodutide significantly reduces the severity of metabolic-associated steatohepatitis (MASH), a severe form of fatty…
Many patients face barriers in accessing treatments for hepatitis C
While highly effective treatments for hepatitis C are available worldwide, many people — especially those living in poorer countries — are not able to access…
Patents covering CM-101, potential PSC therapy, given in Brazil, Israel
Chemomab Therapeutics has been awarded patents in Brazil and Israel covering CM-101, the company’s experimental therapy that’s currently being tested in a Phase…
Protein’s levels in placenta may be key for diagnosing, treating ICP
Intrahepatic cholestasis of pregnancy (ICP), a liver disorder that can affect a pregnant woman, leads to abnormally high levels of a protein called ERp29…
Algorithm for genetic tests helps spot cause of newborn cholestasis
In infants with suspected cholestasis, targeted single-gene testing for those with symptoms that indicate a particular, associated disease and broader gene panel testing for…
Seladelpar lowers levels of molecule driving itch with PBC: Phase 3 trial
Seladelpar, an experimental oral therapy by CymaBay Therapeutics, significantly lowered blood levels of an itch-associated molecule called interleukin-31 (IL-31) in people with…
